Dr. Jeffrey R. Jay, M.D.
Latest statistics and disclosures from Great Point Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are IONS, CYTK, KALV, VRDN, PLRX, and represent 36.76% of Great Point Partners's stock portfolio.
- Added to shares of these 10 stocks: XENE (+$9.6M), IONS (+$8.7M), Upstream Bio, KALV, MREO, RZLT, Optinose, CYTK, UNCY, AUTL.
- Started 5 new stock positions in MREO, XENE, RZLT, Upstream Bio, Optinose.
- Reduced shares in these 10 stocks: ACLX (-$17M), NGNE (-$13M), OLMA (-$12M), PLRX (-$11M), OPTN (-$8.6M), OTLK (-$6.9M), URGN (-$6.1M), DVAX (-$6.0M), ORKA (-$5.5M), TCRX (-$5.1M).
- Sold out of its positions in ACLX, CLYM, OLMA, OPTN, OTLK, RNAC, TCRX, VTGN.
- Great Point Partners was a net seller of stock by $-70M.
- Great Point Partners has $212M in assets under management (AUM), dropping by -37.54%.
- Central Index Key (CIK): 0001281446
Tip: Access up to 7 years of quarterly data
Positions held by Dr. Jeffrey R. Jay, M.D. consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Great Point Partners
Great Point Partners holds 26 positions in its portfolio as reported in the December 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Ionis Pharmaceuticals (IONS) | 8.3 | $18M | +98% | 505k | 34.96 |
|
| Cytokinetics Com New (CYTK) | 8.0 | $17M | +13% | 360k | 47.04 |
|
| Kalvista Pharmaceuticals (KALV) | 7.1 | $15M | +37% | 1.8M | 8.47 |
|
| Miragen Therapeutics (VRDN) | 6.8 | $14M | 750k | 19.17 |
|
|
| Pliant Therapeutics (PLRX) | 6.5 | $14M | -44% | 1.1M | 13.17 |
|
| Abivax Sa Sponsored Ads (ABVX) | 5.7 | $12M | -22% | 1.6M | 7.32 |
|
| Dynavax Technologies Corp Com New (DVAX) | 5.2 | $11M | -35% | 860k | 12.77 |
|
| Neurogene (NGNE) | 4.8 | $10M | -55% | 443k | 22.86 |
|
| Evolus (EOLS) | 4.7 | $9.9M | -23% | 896k | 11.04 |
|
| Xenon Pharmaceuticals (XENE) | 4.5 | $9.6M | NEW | 245k | 39.20 |
|
| Unicycive Therapeutics (UNCY) | 4.1 | $8.7M | +28% | 11M | 0.79 |
|
| Zura Bio Class A Ord Shs (ZURA) | 3.7 | $7.9M | -2% | 3.2M | 2.50 |
|
| Autolus Therapeutics Spon Ads (AUTL) | 3.3 | $7.1M | +7% | 3.0M | 2.35 |
|
| Jasper Therapeutics Com New (JSPR) | 3.2 | $6.9M | 322k | 21.38 |
|
|
| Merus N V (MRUS) | 3.1 | $6.6M | -36% | 158k | 42.05 |
|
| Dianthus Therapeutics (DNTH) | 2.8 | $6.0M | 275k | 21.80 |
|
|
| Helix Acquisition Corp Ii Cl A Ord Shs (HLXB) | 2.5 | $5.3M | 500k | 10.50 |
|
|
| Upstream Bio | 2.3 | $4.9M | NEW | 300k | 16.44 |
|
| Context Therapeutics (CNTX) | 2.3 | $4.9M | -32% | 4.7M | 1.05 |
|
| Voyager Therapeutics (VYGR) | 2.2 | $4.7M | -13% | 827k | 5.67 |
|
| Oruka Therapeutics (ORKA) | 2.1 | $4.4M | -55% | 229k | 19.39 |
|
| Mereo Biopharma Group Spon Ads (MREO) | 1.9 | $4.0M | NEW | 1.2M | 3.50 |
|
| Rezolute Com New (RZLT) | 1.4 | $3.0M | NEW | 622k | 4.90 |
|
| Promis Neurosciences Com New (PMN) | 1.2 | $2.5M | -5% | 2.6M | 0.95 |
|
| Optinose Com New | 1.2 | $2.5M | NEW | 370k | 6.68 |
|
| Urogen Pharma (URGN) | 0.9 | $2.0M | -75% | 188k | 10.65 |
|
Past Filings by Great Point Partners
SEC 13F filings are viewable for Great Point Partners going back to 2013
- Great Point Partners 2024 Q4 filed Feb. 14, 2025
- Great Point Partners 2024 Q3 filed Nov. 13, 2024
- Great Point Partners 2024 Q2 filed Aug. 14, 2024
- Great Point Partners 2024 Q1 filed May 15, 2024
- Great Point Partners 2023 Q4 filed Feb. 14, 2024
- Great Point Partners 2023 Q3 filed Nov. 14, 2023
- Great Point Partners 2023 Q2 filed Aug. 14, 2023
- Great Point Partners 2023 Q1 filed May 15, 2023
- Great Point Partners 2022 Q4 filed Feb. 14, 2023
- Great Point Partners 2022 Q3 filed Nov. 14, 2022
- Great Point Partners 2022 Q2 filed Aug. 15, 2022
- Great Point Partners 2022 Q1 filed May 16, 2022
- Great Point Partners 2021 Q4 filed Feb. 14, 2022
- Great Point Partners 2021 Q3 filed Nov. 15, 2021
- Great Point Partners 2021 Q2 filed Aug. 16, 2021
- Great Point Partners 2021 Q1 filed May 17, 2021